CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Parkinson's disease - Management
How are monoamine oxidase-B inhibitors used in seconday care?
Monoamine oxidase-B inhibitors (selegiline, rasagiline)
- Inhibit central dopamine metabolism, thereby increasing nigrostriatal dopamine levels.
- Do not cause a reaction after consumption of tyramine-rich foods.
- When used as monotherapy in early Parkinson's disease:
- Improve motor symptoms, improve activities of daily living, and delay the need for levodopa. It is less clear whether they also delay motor complications.
- Dopaminergic adverse effects such as dyskinesia, hallucinations, or vivid dreaming may occur or worsen.
- When used as an adjuvant to levodopa in later Parkinson's disease:
- May be used to reduce motor fluctuations although evidence of efficacy is limited.
[National Collaborating Centre for Chronic Conditions, 2006]
© NHS Institute for Innovation and Improvement